Clinical Scorecard: Impact of Anti-Anxiety Treatment on Outcomes in Patients with Atrial Fibrillation and Anxiety: Results from a 2 × 2 Factorial Randomized Controlled Trial

At a Glance

Key Highlights

• Significant improvements in QoL (SF-36) in intervention groups at 6 months (P < 0.01)
• Combination therapy group had lower incidence of Major Adverse Cardiovascular Events (MACE) at 6 months (36.67% vs. 70.00%, P = 0.003)
• Psychological intervention and drug therapy both showed significant main effects on QoL
• Study included 120 patients with AF and anxiety
• Randomized controlled trial design with 2 × 2 factorial approach

Guideline-Based Recommendations

Diagnosis

• Patients diagnosed with AF per 2021 ESC guidelines
• Anxiety assessed using GAD-7 score (≥ 10)

Management

• Consider combined anti-anxiety pharmacotherapy and psychological interventions for AF patients with anxiety

Monitoring & Follow-up

• Evaluate QoL changes using SF-36 at 3 and 6 months

Risks

• Monitor for Major Adverse Cardiovascular Events (MACE) in patients with AF and anxiety

Patient & Prescribing Data

Patients aged 18-80 with paroxysmal, persistent, or long-standing persistent AF and anxiety

Escitalopram and Cognitive Behavioral Therapy (CBT) were used in the intervention groups

Clinical Best Practices

• Integrate psychological care into AF management
• Utilize evidence-based multimodal treatment strategies for patients with comorbidities

Related Resources & Content

• European Society of Cardiology Guidelines